Tudor Investment Corp
BBIO icon

Tudor Investment Corp’s BridgeBio Pharma BBIO Stock Holding History

Tudor Investment Corp’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-124,068
Closed -$6.05M – 3355
2025
Q2 		$5.36M Buy
124,068
+32,736
+36% +$1.19M 0.01% 1052
2025
Q1 		$3.16M Buy
+91,332
New +$3.08M 0.01% 1048
2024
Q2 		– Sell
-22,164
Closed -$685K – 2321
2024
Q1 		$685K Buy
+22,164
New +$754K ﹤0.01% 1509
2023
Q4 		– Sell
-81,150
Closed -$2.14M – 2372
2023
Q3 		$2.14M Buy
+81,150
New +$2.3M 0.02% 895
2023
Q2 		– Sell
-23,321
Closed -$387K – 2427
2023
Q1 		$387K Sell
23,321
-51,187
-69% -$597K 0.01% 1765
2022
Q4 		$568K Sell
74,508
-5,218
-7% -$50K 0.01% 1496
2022
Q3 		$792K Buy
+79,726
New +$828K 0.02% 1075
2022
Q1 		– Sell
-120,372
Closed -$2.01M – 2008
2021
Q4 		$2.01M Buy
120,372
+29,679
+33% +$1.26M 0.03% 620
2021
Q3 		$4.25M Buy
90,693
+43,630
+93% +$2.34M 0.07% 323
2021
Q2 		$2.87M Buy
+47,063
New +$2.69M 0.05% 410

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tudor Investment Corp's BBIO Position: Q3 2025 in Review

Tudor Investment Corp sold out of BridgeBio Pharma (BBIO) in Q3 2025, closing a stake of 124,068 shares — an estimated $6.05M sold.

Tudor Investment Corp first reported a position in BBIO in Q2 2021 and held it in 10 quarters. The position peaked at $5.36M in Q2 2025. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

  • Tudor Investment Corp reported no remaining BridgeBio Pharma position as of Q3 2025 after selling out during the quarter.
  • Tudor Investment Corp sold 124,068 BridgeBio Pharma shares in Q3 2025, an estimated $6.05M.
  • Tudor Investment Corp first reported a position in BridgeBio Pharma in Q2 2021 and held it in 10 quarters.
  • Tudor Investment Corp's BridgeBio Pharma position peaked at $5.36M in Q2 2025.
  • 392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Tudor Investment Corp's 13F filing for Q3 2025, filed 14 Nov 2025.